In the BioHarmony Drug Report Database

"Preview" Icon

Tezacaftor

Symdeko, Kaftrio (tezacaftor) is a small molecule pharmaceutical. Tezacaftor was first approved as Symdeko on 2018-02-12. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator. Symdeko’s patents are valid until 2035-04-14 (FDA).

 

Trade Name

 

Kaftrio
 

Common Name

 

tezacaftor
 

ChEMBL ID

 

CHEMBL3544914
 

Indication

 

cystic fibrosis
 

Drug Class

 

Cystic fibrosis transmembrane regulator (CFTR) protein modulators

Image (chem structure or protein)

Tezacaftor structure rendering